Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis

Current Opinion in Rheumatology

Volumn 27, Issue 2, 2015, Pages 127-133

  Mease, Philip J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

biologics; interleukin 17; interleukin 23; psoriasis; psoriatic arthritis

Indexed keywords

BRODALUMAB; GUSELKUMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; SECUKINUMAB; TILDRAKIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; IMMUNOSUPPRESSIVE AGENT;

ANKYLOSING SPONDYLITIS; BIOLOGICAL THERAPY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; DRUG EFFECTS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ARTHRITIS, PSORIATIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; INTERLEUKIN-23; MOLECULAR TARGETED THERAPY; PSORIASIS; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84922410788     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000147     Document Type: Review

References (33)

1. Rouvier E, Luciani MF, Mattei MG, et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993; 150:5445-5456.
2. van den Berg WB, McInnes IB. Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013; 43:158-170.
3. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888-898.
4. Frleta M, Siebert S, McInnes IB. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr Rheumatol Rep 2014; 16:414.
5. Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013; 72 (Suppl 2): ii116-ii123.
6. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat CD3CD4-CD8- entheseal resident T cells. Nat Med 2012; 18:1069-1076.
7. Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med 2012; 18:1018-1019.
8. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68:777-783.
9. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361:496-509.
10. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013; 44:183-193.
11. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008; 58:2307-2317.
12. Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 2014; 13 (4-5):496-502.
13. Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, doubleblind, randomised, placebo controlled study. Ann Rheum Dis 2013; 72: 863-869.
14. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-1684.
15. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780-789.
16. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiological and biological antitumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73:990-999.
17. Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014; 73:1000-1006.
18. Podubbnyy D, Callhoff J, Listing J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Arthritis Rheumatol 2013; 65 (10 (Suppl)):S766.
19. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med 2014; 371:326-338.
20. Mease P, McInnes I, Kirkham B, et al. Secukinumab, a human anti-interleukin- 17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 2014; 66 (Suppl):S423. Abstract 953.
21. van der Heijde D, Landewe R, Mease P, et al. Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-cotrolled sudy. Arthritis Rheum 2014; 66 (Suppl):S424. Abstract 954.
22. McInnes IB, Mease P, Kirkham B, et al. Secukinumab, a human anti-interleukin- 17A monoclonal antibody, improves active psoriatic arthritis: 24-week efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using subcutaneous dosing. Late breaking oral presentation at: ACR/ARHP Annual Meeting, Boston, MA, USA, 2014. Presentation number L1.
23. Baeten D, Braun J, Baraliakos X, et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Arthritis Rheum 2014; 66 (Suppl):S360. Abstract 819.
24. Sieper J, Braun J, Baraliakos X, et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing. Arthritis Rheum 2014; 66 (Suppl):S232. Abstract 536.
25. Leonardi C, Matheson R, Zachariae C, et al. Antiinterleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190-1199.
26. Genovese MC, Greenwald M, Cho CS, et al. A phase II randomized study of subcutaneous ixekizumab, an antiinterleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheum 2014; 66:1693-1704.
27. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an antiinterleukin-17- receptor antibody for psoriasis. N Engl J Med 2012; 366:1181-1189.
28. Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370:2295-2306.
29. Martin DA, Churchill M, Flores-Suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013; 15:R164.
30. Pavelka K, Chon Y, Newmark R, et al. A randomized, double-blind, placebocontrolled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate (abstract 831). Arthritis Rheum 2012; 64
31. Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-tosevere psoriasis. J Allergy Clin Immunol 2014; 133:1032-1040.
32. Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg 2014; 18:156-169. An excellent review of emerging therapies along the TH17 pathway.
33. Leonardi CL, Gordon KB. New and emerging therapies in psoriasis. Semin Cutan Med Surg 2014; 33 (Suppl 2):S37-S41.